Skip to content
10-Q

Quarterly Report

Turn Therapeutics Inc. TTRX

0001213900-26-054490

← back to feed
Filed
May 11, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 8, 2026 29.79M sh
Shares Diluted Q1 2026 · Mar 31, 2026 29.48M sh
Shares Diluted Q1 2026 · Mar 31, 2025 26.96M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$1.63M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$298.06K
Long Term Debt Q1 2026 · Mar 31, 2026 $5.94M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $11.01M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $4.03M
Stockholders Equity Q1 2026 · Mar 31, 2026 $6.12M
Stockholders Equity Q1 2026 · Dec 31, 2025 $4.69M
Stockholders Equity Q1 2026 · Mar 31, 2025 $818.71K
Stockholders Equity Q1 2026 · Dec 31, 2024 −$177.43K
Current Liabilities Q1 2026 · Mar 31, 2026 $5.13M
Current Liabilities Q1 2026 · Dec 31, 2025 $6M
Total Liabilities Q1 2026 · Mar 31, 2026 $12.53M
Total Liabilities Q1 2026 · Dec 31, 2025 $7.48M
Current Assets Q1 2026 · Mar 31, 2026 $11.45M
Current Assets Q1 2026 · Dec 31, 2025 $5.2M
Total Assets Q1 2026 · Mar 31, 2026 $18.64M
Total Assets Q1 2026 · Dec 31, 2025 $12.16M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.03
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.01
Eps Basic Q1 2026 · Mar 31, 2026 −$0.03
Eps Basic Q1 2026 · Mar 31, 2025 −$0.01
Sga Expense Q1 2026 · Mar 31, 2026 $1.14M
Sga Expense Q1 2026 · Mar 31, 2025 $375.74K
Rd Expense Q1 2026 · Mar 31, 2026 $109.43K
Rd Expense Q1 2026 · Mar 31, 2025 $9.26K
Net Income Q1 2026 · Mar 31, 2026 −$970.97K
Net Income Q1 2026 · Mar 31, 2025 −$328.55K
Operating Income Q1 2026 · Mar 31, 2026 −$1.25M
Operating Income Q1 2026 · Mar 31, 2025 −$385K